-
-
Overview
-
Antigen Distribution: FcγRIV is expressed on the cell membrane of splenic and bone marrow dendritic cells, monocytes, and macrophages as well as peripheral blood monocytes, neutrophils, thioglycollate-elicited macrophages, and myeloid cells. FcγRIV is absent from lymphoid populations, T cells, B cells, NK cells, and other granulocytes.
Specificity: 9E9 activity is primarily directed against mouse CD16.2 / FcγRIV but can also bind and block FcγRIII in vivo.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Armenian Hamster IgG Isotype Control for In Vivo - Low Endotoxin [PIP] (ICH2251)
Endotoxin: ≤ 0.5 EU/mg as determined by the LAL method
Aggregation: Aggregation level ≤ 1%Please contact us at for specific academic pricing.
Background
According to surface plasmon resonance, 9E9 has strong reactivity to FcγRIV as well as low level binding to FcγRII and FcγRIII. In vivo, 9E9 binds and blocks FcγRIII only when 9E9 first binds FcγRIV on the same effector cell, resulting in concurrent inhibition of FcγRIII and FcγRIV. Native 9E9 binds to FcγRII and FcγRIII via the Fc.
Blocking studies with 9E9 show that FcγRIV is necessary for IgG2a and IgG2b mediated platelet clearance in vivo. Additionally, blocking FcγRIV with 9E9 reduces B-cell depletion. 9E9 also interferes with immune complex binding to FcγRIV and can block FcγRIII on macrophages and neutrophils.
-
- Properties
- Applications
-
Overview